Anaplastic lymphoma kinase rearranged non-small-cell lung cancer is a rare disease. Among them, a subset of patients exist who exhibit relatively slowly progressing symptoms and have oligo-metastases. In this article, we present two cases of ALK rearran-ged lung adenocarcinoma in patients who experienced postoperative oligo-recurrence. Both cases were treated with surgical resection and gamma knife irradiation for oligo-recurrence. After local therapy, the first patient remained disease free for over 23 months; the second for over 18 months. It appears that some patients with ALK rearranged NSCLC experience oligo-recurrence in their clinical course. For such patients, appropriate local therapy may be beneficial in improving both the qualit...
This meta-analysis aimed to comprehensively examine the relationship between the clinicopathological...
This meta-analysis aimed to comprehensively examine the relationship between the clinicopathological...
Assessment of ALK gene rearrangements is strongly recommended by the Molecular Testing Guideline for...
Introduction: Survival of ALK-rearranged NSCLC patients has dramatically improved by the use of mult...
Since its discovery in 2007, we have seen the lives of patients diagnosed with advanced anaplastic l...
Background Anaplastic lymphoma kinase (ALK) rearrangements are known oncogenic drivers in non-sma...
Personalized treatment based on driver molecular alterations, such as ALK rearrangement, has revolut...
Since its discovery in 2007, we have seen the lives of patients diagnosed with advanced anaplastic l...
Aim: To report on the pattern of care and survival of anaplastic lymphoma kinase rearranged non-smal...
Background: In Finland approximately 2,500 people are diagnosed with lung cancer annually. A small p...
Background and objective Anaplastic lymphoma kinase (ALK) is an important therapeutic target for adv...
Rearrangements of the anaplastic lymphoma kinase (ALK) gene account for 5-6% in non-small cell lung ...
Rearrangements of the anaplastic lymphoma kinase (ALK) gene are present in 3% to 7% of nonsmall-cell...
Bin Yao,1 Xue Han,2 Linrong Pang,1 Caihong Xu,1 Sisi Liu,2 Xiaochun Cheng,1 Jun Chen1 1Department of...
Kangqi Ren,1,* Guanggui Ding,1,* Shuying Xie,2 Lin Yang1 1Department of Thoracic Surgery, Sh...
This meta-analysis aimed to comprehensively examine the relationship between the clinicopathological...
This meta-analysis aimed to comprehensively examine the relationship between the clinicopathological...
Assessment of ALK gene rearrangements is strongly recommended by the Molecular Testing Guideline for...
Introduction: Survival of ALK-rearranged NSCLC patients has dramatically improved by the use of mult...
Since its discovery in 2007, we have seen the lives of patients diagnosed with advanced anaplastic l...
Background Anaplastic lymphoma kinase (ALK) rearrangements are known oncogenic drivers in non-sma...
Personalized treatment based on driver molecular alterations, such as ALK rearrangement, has revolut...
Since its discovery in 2007, we have seen the lives of patients diagnosed with advanced anaplastic l...
Aim: To report on the pattern of care and survival of anaplastic lymphoma kinase rearranged non-smal...
Background: In Finland approximately 2,500 people are diagnosed with lung cancer annually. A small p...
Background and objective Anaplastic lymphoma kinase (ALK) is an important therapeutic target for adv...
Rearrangements of the anaplastic lymphoma kinase (ALK) gene account for 5-6% in non-small cell lung ...
Rearrangements of the anaplastic lymphoma kinase (ALK) gene are present in 3% to 7% of nonsmall-cell...
Bin Yao,1 Xue Han,2 Linrong Pang,1 Caihong Xu,1 Sisi Liu,2 Xiaochun Cheng,1 Jun Chen1 1Department of...
Kangqi Ren,1,* Guanggui Ding,1,* Shuying Xie,2 Lin Yang1 1Department of Thoracic Surgery, Sh...
This meta-analysis aimed to comprehensively examine the relationship between the clinicopathological...
This meta-analysis aimed to comprehensively examine the relationship between the clinicopathological...
Assessment of ALK gene rearrangements is strongly recommended by the Molecular Testing Guideline for...